SAXENDA (Liraglutide), Drug Insight and Market Forecast - 2032

“SAXENDA (Liraglutide), Drug Insight and Market Forecast - 2032” report provides comprehensive insights about SAXENDA (Liraglutide) for Obesity in the 7MM. A detailed picture of the SAXENDA (Liraglutide) for Obesity in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019-2032 is provided in this report along with a detailed description of the SAXENDA (Liraglutide) for Obesity. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the SAXENDA (Liraglutide) market forecast, analysis for Obesity in the 7MM, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Obesity.

Drug Summary

SAXENDA (Liraglutide) is a Glucagon-like Peptide 1 (GLP-1) receptor agonist indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial Body Mass Index (BMI) of 30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g. hypertension, type 2 diabetes mellitus, or dyslipidemia) and pediatric patients aged 12 years and older with a body weight above 60 kg, and an initial BMI corresponding to 30 kg/m2 for adults (obese) by international cut-off.

SAXENDA is recommended at a dose of 3 mg per day. It is recommended to start with 0.6 mg per day for one week. The dose should be increased at weekly intervals until a dose of 3 mg is reached. If pediatric patients are unable to tolerate an increased dose during dose escalation, the dose may be reduced to the previous level. Pediatric patients may require dose escalation for up to 8 weeks. Pediatric patients who are unable to tolerate 3 mg per day may have their dose reduced to 2.4 mg per day.

Liraglutide is an acylated human Glucagon-like Peptide-1 (GLP-1) receptor agonist with 97% amino acid sequence homology to endogenous human GLP-1(7-37). Like endogenous GLP-1, liraglutide binds to and activates the GLP-1 receptor, a cell-surface receptor coupled to adenylyl cyclase activation through the stimulatory G-protein, Gs. Endogenous GLP-1 has a half-life of 1.5-2 minutes due to degradation by the ubiquitous endogenous enzymes, Dipeptidyl Peptidase 4 (DPP-4) and Neutral Endopeptidases (NEP). Unlike native GLP-1, liraglutide is stable against metabolic degradation by both peptidases and has a plasma half-life of thirteen hours after subcutaneous administration. The pharmacokinetic profile of liraglutide, which makes it suitable for once-daily administration, is a result of self-association that delays absorption, plasma protein binding, and stability against metabolic degradation by DPP-4 and NEP.

GLP-1 is a physiological regulator of appetite and calorie intake, and the GLP-1 receptor is present in several areas of the brain involved in appetite regulation. In animal studies, peripheral administration of liraglutide resulted in the presence of liraglutide in specific brain regions regulating appetite, including the hypothalamus. Although liraglutide activated neurons in brain regions known to regulate appetite, specific brain regions mediating the effects of liraglutide on appetite were not identified in rats.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the SAXENDA (Liraglutide) description, mechanism of action, dosage and administration, research and development activities in Obesity.
• Elaborated details on SAXENDA (Liraglutide) regulatory milestones and other development activities have been provided in this report.
• The report also highlights the SAXENDA (Liraglutide) research and development activity in Obesity in detail across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around SAXENDA (Liraglutide).
• The report contains forecasted sales of SAXENDA (Liraglutide) for Obesity till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Obesity.
• The report also features the SWOT analysis with analyst views for SAXENDA (Liraglutide) in Obesity.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by the publisher's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

SAXENDA (Liraglutide) Analytical Perspective

In-depth SAXENDA (Liraglutide) Market Assessment

This report provides a detailed market assessment of SAXENDA (Liraglutide) in Obesity in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2022 to 2032.

SAXENDA (Liraglutide) Clinical Assessment

The report provides the clinical trials information of SAXENDA (Liraglutide) in Obesity covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for Obesity is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence SAXENDA (Liraglutide) dominance.
• Other emerging products for Obesity are expected to give tough market competition to SAXENDA (Liraglutide) and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of SAXENDA (Liraglutide) in Obesity.
• The in-depth analysis of the forecasted sales data of SAXENDA (Liraglutide) from 2022 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the SAXENDA (Liraglutide) in Obesity.

Key Questions Answered

• What is the product type, route of administration and mechanism of action of SAXENDA (Liraglutide)?
• What is the clinical trial status of the study related to SAXENDA (Liraglutide) in Obesity and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the SAXENDA (Liraglutide) development?
• What are the key designations that have been granted to SAXENDA (Liraglutide) for Obesity?
• What is the forecasted market scenario of SAXENDA (Liraglutide) for Obesity?
• What are the forecasted sales of SAXENDA (Liraglutide) in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available in Obesity and how are they giving competition to SAXENDA (Liraglutide) for Obesity?
• Which are the late-stage emerging therapies under development for the treatment of Obesity?

This product will be delivered within 2 business days.